A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX2

Vitale, Emanuele; Sauta, Elisabetta; Gugnoni, Mila; Torricelli, Federica; Manicardi, Veronica; Ciarrocchi, Alessia

doi:10.1002/cac2.12292

Cited by 7 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…RUNX2 has a key role in the development of bone and cartilage tissue, while abnormal expression of RUNX2 is associated with a variety of cancer types, and in particular, the process of tumor bone metastasis (41). To date, RUNX2 has been proven to be involved in melanoma, thyroid cancer and hepatocellular carcinoma (42)(43)(44). For instance, Guan et al (44) found that circular (circ) RNA_102272 promoted cisplatin resistance of hepatocellular carcinoma via inhibiting the targeting effect of microRNA (miR)-326 upon RUNX2.…”

Section: The Runx Familymentioning

confidence: 99%

Role of RUNX2 in breast cancer development and drug resistance (Review)

Chen

Zhang

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

Breast cancer is the most common malignancy and ranks second among the causes of tumor-associated death in females. The recurrence and drug resistance of breast cancer are intractable due to the presence of breast cancer stem cells (BCSCs), which are adequate to initiate tumor formation and refractory to conventional remedies. Runt-related transcription factor 2 (RUNX2), a pivotal transcription factor in mammary gland and bone development, has also been related to metastatic cancer and BCSCs. State-of-the-art research has indicated the retention of RUNX2 expression in a more invasive subtype of breast cancer, and in particular, triple-negative breast cancer development and drug resistance are associated with estrogen receptor signaling pathways. The present review mainly focused on the latest updates on RUNX2 in BCSCs and their roles in breast cancer progression and drug resistance, providing insight that may aid the development of RUNX2-based diagnostics and treatments for breast cancer in clinical practice. Contents1. Introduction 2. Breast cancer and classification 3. Status of clinical treatment of breast cancer 4. The RUNX family 5. Physiological and pathological roles of RUNX2 6. BCSCs 7. Drug resistance in breast cancer 8. Discussion

show abstract

Section: The Runx Familymentioning

confidence: 99%

Role of RUNX2 in breast cancer development and drug resistance (Review)

Chen

Zhang

et al. 2023

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…ChIP‐Seq data processing was performed as previously described [19]. Briefly, sequencing quality was assessed using the fastqc v0.11.8 software (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), showing on average a Phred score per base > 30.5 in each sample.…”

Section: Methodsmentioning

confidence: 99%

“…ChIP-Seq data processing was performed as previously described [19]. Briefly, sequencing quality was assessed using the FASTQC v0.11.8 software (www.bioinformatics.…”

Section: Chip-seq Data Processingmentioning

confidence: 99%

Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis

et al. 2023

Self Cite

View full text Add to dashboard Cite

Mortality from vmelanoma is associated with metastatic disease, but the mechanisms leading to spreading of the cancer cells remain obscure. Spatial profiling revealed that melanoma is characterized by a high degree of heterogeneity, which is established by the ability of melanoma cells to switch between different phenotypical stages. This plasticity, likely a heritage from embryonic pathways, accounts for a relevant part of the metastatic potential of these lesions, and requires the rapid and efficient reorganization of the transcriptional landscape of melanoma cells. A large part of the non‐coding genome cooperates to control gene expression, specifically through the activity of enhancers (ENHs). In this study, we aimed to identify ex vivo the network of active ENHs and to outline their cooperative interactions in supporting transcriptional adaptation during melanoma metastatic progression. We conducted a genome‐wide analysis to map active ENHs distribution in a retrospective cohort of 39 melanoma patients, comparing the profiles obtained in primary (N = 19) and metastatic (N = 20) melanoma lesions. Unsupervised clustering showed that the profile for acetylated histone H3 at lysine 27 (H3K27ac) efficiently segregates lesions into three different clusters corresponding to progressive stages of the disease. We reconstructed the map of super‐ENHs (SEs) and cooperative ENHs that associate with metastatic progression in melanoma, which showed that cooperation among regulatory elements is a mandatory requirement for transcriptional plasticity. We also showed that these elements carry out specialized and non‐redundant functions, and indicated the existence of a hierarchical organization, with SEs on top as masterminds of the entire transcriptional program and classical ENHs as executors. By providing an innovative vision of how the chromatin landscape of melanoma works during metastatic spreading, our data also point out the need to integrate functional profiling in the analysis of cancer lesions to increase definition and improve interpretation of tumor heterogeneity.

show abstract

“…RUNX2 is essential for the growth of bone and cartilage, and it promotes the spread of tumors to bones [ 11 ]. RUNX2 has been linked to many different malignancies, including melanoma, thyroid, and liver tumors [ 12 , 13 ]. According to Guan et al [ 14 ], circ RNA_102272 enhanced the cisplatin resistance of hepatocellular carcinoma via blocking miR-326’s influence on RUNX2.…”

Section: The Runx Familymentioning

confidence: 99%

RUNX Family as a Promising Biomarker and a Therapeutic Target in Bone Cancers: A Review on Its Molecular Mechanism(s) behind Tumorigenesis

Vimalraj

Sekaran

2023

Cancers

View full text Add to dashboard Cite

The transcription factor runt-related protein (RUNX) family is the major transcription factor responsible for the formation of osteoblasts from bone marrow mesenchymal stem cells, which are involved in bone formation. Accumulating evidence implicates the RUNX family for its role in tumor biology and cancer progression. The RUNX family has been linked to osteosarcoma via its regulation of many tumorigenicity-related factors. In the regulatory network of cancers, with numerous upstream signaling pathways and its potential target molecules downstream, RUNX is a vital molecule. Hence, a pressing need exists to understand the precise process underpinning the occurrence and prognosis of several malignant tumors. Until recently, RUNX has been regarded as one of the therapeutic targets for bone cancer. Therefore, in this review, we have provided insights into various molecular mechanisms behind the tumorigenic role of RUNX in various important cancers. RUNX is anticipated to grow into a novel therapeutic target with the in-depth study of RUNX family-related regulatory processes, aid in the creation of new medications, and enhance clinical efficacy.

show abstract

A multimodal integrative approach to model transcriptional addiction of thyroid cancer on RUNX2

Cited by 7 publications

References 10 publications

Role of RUNX2 in breast cancer development and drug resistance (Review)

Role of RUNX2 in breast cancer development and drug resistance (Review)

Ex vivo mapping of enhancer networks that define the transcriptional program driving melanoma metastasis

RUNX Family as a Promising Biomarker and a Therapeutic Target in Bone Cancers: A Review on Its Molecular Mechanism(s) behind Tumorigenesis

Contact Info

Product

Resources

About